Role of intrathecal nalbuphine on prevention of postspinal shivering after knee arthroscopy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201505001091143

Enrollment

Registered

2015-03-31

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery nalbuphine, shivering Anaesthesia

Interventions

bupivacaine 0.5%

bupivacaine 0.5%+nalbuphine 400 microgram

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20-60 years of both sex and ASA(American Society of Anesthesia) physical status I or II scheduled for knee arthroscopy under spinal anaesthesia

Exclusion criteria

Exclusion criteria: Patients with contraindications to regional anaesthesia, allergy to the study medication, obese with body mass index (BMI) >30 were excluded.

Design outcomes

Primary

Measure	Time frame
incidence of shivering	—

Secondary

Measure	Time frame
severity of shivering	—

Countries

Egypt

Contacts

Public Contactahraf eskandr

lecturer of anesthesia, icu, menoufiya faculty of medicine

ameskandr@yahoo.com00201001960697

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026